Basel Medical Group Ltd (BMGL) received a Nasdaq delinquency notice on December 1 2025 for an incomplete Form 20‑F filing, which lacked the required auditor’s opinion from NLA DFK Assurance PAC.
The notice grants the company 60 days to submit a compliance plan, with a possible 180‑day extension if approved, underscoring the risk to its Nasdaq listing status and investor confidence.
The missing auditor’s opinion arose after NLA DFK Assurance PAC was appointed on June 30 2025; BMGL is coordinating with its accounting, audit, and legal teams to prepare a rectification plan to address the shortfall.
For the fiscal year ended June 30 2025, BMGL reported revenue of $9.52 million, up 16% from $8.00 million, but posted a net loss of $12.09 million versus a profit of $2.07 million in the prior year, highlighting ongoing financial challenges.
BMGL operates seven clinics in Singapore offering orthopedic, trauma, sports medicine, and neurosurgical services. The compliance issue adds to investor concerns amid a market capitalization of $22.36 million and a significant decline in market value over the past year.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.